echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The new crown vaccine can be mixed, but after all, there is no mRNA vaccine

    The new crown vaccine can be mixed, but after all, there is no mRNA vaccine

    • Last Update: 2022-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    State Council Joint Prevention and Control Mechanism Holds Press Conference

    The Joint Prevention and Control Mechanism of the State Council Holds a Press Conference The Joint Prevention and Control Mechanism of the State Council Holds a Press Conference

    Guide:

    Guide:

    On February 19, the Joint Prevention and Control Mechanism of the State Council held a press conference to introduce the situation of epidemic prevention and control and vaccination
    .


    The focus of this conference is that the new crown vaccine can be mixed


    The new crown vaccine can be mixed and the new crown vaccine can be mixed, so which ones can be vaccinated? So what can be vaccinated?

    The two vaccines were approved for emergency use on March 17, 2021, and approved for marketing on February 25, 2021
    .

    It can be expected that a new round of vaccination work is about to start
    .


    Different from the previous booster shots, according to the sequential vaccination situation, we can choose to inoculate different batches of vaccines from previous batches.


    As for why there is no new crown mRNA listed this time? First of all, the domestic new crown mRNA vaccine has not yet completed the phase 3 clinical trial (the phase 3 clinical trial has been carried out abroad), but because the phase I clinical data is somewhat unsatisfactory, and the epidemic situation is still very anxious, so it has not been selected for emergency approval.
    Second, although the Phase 1 clinical trial of the mRNA vaccine jointly developed by Fosun Pharma and Germany's BioNtech has been completed in China, the follow-up progress of the vaccine is not yet known, so it has not been approved or marketed urgently in China.
    permission
    .

    Why is there no new crown mRNA listed? Why is there no new crown mRNA listed?

    In Europe, America and other regions, on the whole, the safety and efficacy of the new crown mRNA vaccine is good, and it can effectively deal with the mutant strain of the new crown virus, but this problem in China will not be solved in a short period of time, and ordinary people will Facing a situation where there is no mRNA vaccine available
    .

    Despite this, many domestic biological companies are still very optimistic about this track, stepping up the development of new crown mRNA vaccines and expanding this mRNA technology to other application fields
    .

    The following is the content of the press conference held by the joint prevention and control mechanism of the State Council, as well as the introduction of what sequential immunization is and who can receive sequential immunization
    .

    On February 19, the Joint Prevention and Control Mechanism of the State Council held a press conference to introduce the situation of epidemic prevention and control and vaccination
    .


    What is the recent national epidemic situation? What is sequential immunization? Who can receive sequential booster immunizations?

    What is the recent national epidemic situation? What is sequential immunization? Who can receive sequential booster immunizations? What is the recent national epidemic situation? What is sequential immunization? Who can receive sequential booster immunizations?

    01

    01

    What is the recent national epidemic situation?

    What is the recent national epidemic situation?

    The epidemic situation in Baise, Guangxi is in the final stage of clearing
    .

    The recent new cases in Huludao, Liaoning Province were mainly found through centralized isolation and screening.
    The epidemic trend is improving, and the risk of social transmission is basically under control
    .

    At present, the epidemic situation in Heihe, Heilongjiang is mainly concentrated in Heihe City, and there are multiple chains of transmission.
    Further epidemiological tracing and case investigation are being carried out in an orderly manner
    .

    In Guangdong, Shenzhen, Zhuhai, and Dongguan have recently experienced a cluster of epidemics caused by overseas imports.
    The Shenzhen Omicron-related epidemic has basically been controlled.
    The epidemic in Dongguan and Zhuhai is strengthening the work of tracing the source of the epidemic, and making every effort to prevent the spread of the epidemic
    .

    Epidemic outbreaks have occurred in Wenshan, Honghe and Ruili in Yunnan, and the source of infection is still unclear.
    The local area is making every effort to speed up nucleic acid screening in key areas, speed up the investigation of risk sources, and prevent the epidemic from spreading from border areas to inland areas
    .

    The genetic sequencing result of the epidemic in Suzhou, Jiangsu is a variant of Omicron, which is a local epidemic caused by a new overseas import source, and is still in a stage of rapid development
    .


    The local area is speeding up the work of tracing the source of the epidemic, expanding nucleic acid screening in risk areas, and strengthening the inspection of personnel in key places to prevent the further spread of the epidemic


    The gene sequencing result of the epidemic in Hohhot, Inner Mongolia, is a delta variant, which is a local epidemic caused by a new overseas import source, which has spread to Baotou City, Inner Mongolia
    .


    At present, the epidemic is in an early stage, the number of cases is growing rapidly, and there are clusters of epidemics in places with dense crowds such as work units and wedding banquets.


    At present, the working group dispatched by the comprehensive group of the joint prevention and control mechanism of the State Council has jointly dealt with the clustered epidemics in Liaoning, Inner Mongolia, Guangdong and other provinces and regions, and guided the implementation of various measures
    .

    02

    02

    What is sequential immunization?

    What is sequential immunization?

    Sequential immunization is an immunization strategy adopted by vaccines of different technical routes according to a certain vaccination interval and doses, in order to further improve the preventive effect and consider safety
    .

    Generally, for conventional viruses or diseases that are easy to deal with, a single vaccine is enough, but for some viruses that are highly variable and difficult to deal with, sequential immunization is often used
    .


    Mainly for two purposes:

    1.
    First, the advantages of different vaccines can complement each other;

    2.
    In addition, individuals with different constitutions may have more side effects on a certain type of vaccine.
    In this way, changing a vaccine can avoid side effects
    .

    Recently, with the approval of the Joint Prevention and Control Mechanism of the State Council, the National Health Commission has begun to deploy sequential booster immunizations
    .

    03

    03

    Who can receive sequential booster immunizations?

    Who can receive sequential booster immunizations?

    The objects of this sequence of immunization are: first, people over 18 years old, and second, who have completed 2 doses of inactivated vaccine, and these 2 doses were vaccinated by Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, and Sinopharm Zhongsheng Wuhan The company's new coronavirus inactivated vaccine
    .


    The third is to complete 2 doses of vaccination in the whole process, and the interval between sequential booster immunizations cannot be shorter than 6 months


    Previously, all target groups over the age of 18 who have been vaccinated with Sinopharm Zhongsheng Beijing Company, Wuhan Company, Beijing Kexing Company's inactivated vaccine, and Tianjin CanSino Company's adenovirus vector vaccine for 6 months can receive one dose of homology.
    A booster immunization is a booster with the original vaccine
    .

    After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of inoculation with the above three inactivated vaccines can also choose the recombinant protein vaccine of Zhifeilong Kema or the adenovirus vector vaccine of CanSino for sequential booster immunization
    .

    For the target population, one of homologous booster immunization and sequential booster immunization can be selected
    .

    Research data shows that both homologous booster immunization and sequential booster immunization can further improve the immune effect.
    It is hoped that people who meet the vaccination conditions can be vaccinated actively and early
    .

    04

    04

    What are the characteristics of the Omicron case?

    What are the characteristics of the Omicron case?

    First, it is more contagious and spreads faster
    .


    The generation interval between Omicron infection cases is 3 days on average, which is further shortened than the 4 days of the delta variant, and its transmission ability is about twice that of the delta variant


    More contagious and spread faster

    Second, the symptoms of Omicron infection are atypical and therefore more insidious during transmission
    .


    From the perspective of clinical manifestations, the infection of the Omicron strain is similar to the symptoms of upper respiratory tract infection caused by other viruses, lacks specific manifestations, and the clinical differential diagnosis is relatively difficult, and the virus transmission becomes more insidious


    Symptoms of Omicron infection are atypical and therefore more insidious during transmission

    Third, the cases are mainly mild and common, and the symptoms are relatively mild.
    The main clinical manifestations are cough, sore throat, fever, etc.
    , and some patients have symptoms such as nasal congestion, runny nose, fatigue, and headache
    .
    In addition, the patient's imaging changes were not typical
    .
    Overall, the proportion of critically ill patients is not very high
    .
    However, because it spreads quickly, once it causes population transmission, it may cause a run on medical resources
    .

    The cases are mainly mild and common, and the symptoms are relatively mild.
    The main clinical manifestations are cough, sore throat, fever, etc.
    Some patients have symptoms such as nasal congestion, runny nose, fatigue, and headache.

    At present, the Omicron variant has become the dominant strain of imported and local epidemics in China, and its transmission is stronger and faster
    .
    The risk of imported epidemics and local epidemics in China has increased significantly
    .

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.